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Introduction
D-dimer is a final plasmin-mediated fibrin degra-
dation product consisting of two covalently bound 
fibrin D domains, cross-linked by factor XIII during 
clot formation (1-3).
In conjunction with clinical pre-test probability, 
measurement of D-dimers is a key non-invasive di-
agnostic test to rule out venous thromboembo-
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lism (VTE) and pulmonary embolism (PE), as well 
as an aid in the diagnosis of disseminated intravas-
cular coagulopathy (2-5). However, high D-dimer 
values are associated with several other conditions 
related to hyperactivation of blood coagulation 
and fibrinolysis, such as inflammation, trauma, sur-
gery, pregnancy complications, malignancies, or 
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vascular abnormalities, making their positive pre-
dictive value rather poor (3,5-7). In healthy individ-
uals small amounts of fibrinogen are on daily basis 
physiologically converted to fibrin, resulting in de-
tectable plasma D-dimer concentrations that in-
crease with age (8).
Albeit the fact that microplate enzyme-linked im-
munosorbent assay (ELISA) is still the gold standard 
method for the quantitative determination of D-di-
mers due to its highest sensitivity, it is time-con-
suming, non-automated, characterized by a high 
level of analytical imprecision, and therefore not 
suitable for routine practice (1). The enzyme-linked 
immunofluorescent assay (ELFA) is a semi-automat-
ed ELISA assay with fluorescence endpoint detec-
tion, that exhibits similar sensitivity and specificity 
to ELISA and is considered the reference commer-
cial D-dimer assay (1,9). However, the need for rapid 
turnaround time and the possibility of analysing D-
dimers along with other routine coagulation tests 
on the same analytical platform makes the recently 
available latex-enhanced particle immunoturbidi-
metric (LPIA) assays attractive to laboratory profes-
sionals (1). Numerous available D-dimer assays on 
the market differ significantly by the specificity of 
capture monoclonal antibodies used, their reactivi-
ty to different fibrin degradation products, method 
endpoint detection, and calibration standard used, 
still making standardization of D-dimer assays an 
unsolved issue (1-3,5,10). Thereby, it is of upmost im-
portance to assess the analytical performance of 
any D-dimer assay prior to implementation into 
routine practice, as well as the comparability of re-
sults, whenever switching from one to another ana-
lytical method. 
This study was performed with the aim to perform 
the analytical verification of two automated LPIA 
D-dimer assays and assess their comparability 
with the routinely used ELFA method.
Materials and methods
Setting and description of assays
The study was conducted at the Department of 
Laboratory Diagnostics of the University Hospital 
Centre Zagreb, Croatia. 
The INNOVANCE D-dimer assay (Siemens Health-
care, Marburg, Germany) was performed accord-
ing to the original manufacturer’s application on 
Sysmex CS-5100 and Atellica COAG 360 coagula-
tion analysers, both produced by Siemens Health-
care, Marburg, Germany. Polystyrene particles co-
valently coated with 8D3 monoclonal antibody are 
aggregated in the presence of D-dimer in the sam-
ple, which is measured as a decrease of light trans-
mission at 630 nm. For samples with D-dimer con-
centrations within the measuring range from 0.19 
to 4.40 mg/L fibrinogen equivalent units (FEU) re-
sults are available within 7 minutes. Automated 
sample redilution extends the measuring range 
up to 35.2 mg/L FEU, with a total sample analysis 
time of 14 minutes (11). Since a D-Dimer interna-
tional standard is not available, INNOVANCE D-di-
mer calibrator is traceable to a company internal 
primary master standard containing a pool of pa-
tient samples that fulfil the requirements of diag-
nostic sensitivity and specificity at the cut-off. A 
secondary master standard is calibrated against it 
and, following verification of normal range, is used 
as the product calibrator (12). The interference 
study performed by the manufacturer proved no 
effect of rheumatoid factor (RF) up to 1330 IU/mL 
on assay results.
The HemosIL D-Dimer HS 500 (Instrumentation 
Laboratory, Milan, Italy) is a fully automated LPIA 
assay that was used on an ACL TOP 550 analyser 
(Instrumentation Laboratory S.p.A. – Werfen, Mi-
lan, Italy). The reagent consists of a suspension of 
polystyrene latex particles coated with F(ab’)2 
fragment of the 8D3 monoclonal antibody that 
binds the cross-linked D-dimer domain. The de-
gree of agglutination is directly proportional to 
the concentration of D-dimer in plasma and is 
measured as the decrease of the light transmitted 
at 671 nm. Results are available within 5 minutes, if 
no rerun is performed. The assay measuring range 
is from 0.22 to 7.65 mg/L FEU, which can be ex-
tended by automatic sample dilution up to 128 
mg/L FEU, with a final result obtained within 10 
minutes from the start of analysis (13). The D-dim-
er HS 500 calibrator is traceable to an internal 
house standard composed of a pool of patients 
plasma and assigned according to the proposed 
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harmonisation procedure (14,15). It is declared that 
RF does not have an interfering effect on assays re-
sults at concentrations below 1400 IU/mL.
The VIDAS D-Dimer Exclusion II assay used on the 
miniVidas analyser (both from bioMérieux, Marcy-
l’Étoile, France) is based on the ELFA principle. It is 
a two-step enzyme immunoassay that utilizes two 
monoclonal anti-fibrin degradation products anti-
bodies (10B5E12C9 coated on the solid phase and 
alkaline phosphatase-labelled antibody 2C5A10) 
and final fluorescent detection. Contrary to the 
previous two LPIA assays, analysis of D-dimers by 
its means is a semi-automated procedure that re-
quires manual sample pipetting in the appropriate 
test strip well. Results are available within 20 min-
utes, and the assay is linear from 0.05 to 10.0 mg/L 
FEU. Additionally, samples with D-dimer concen-
trations above the upper quantification limit can 
be manually diluted with the appropriate diluent 
in the ratio 1:5 and reanalysed, achieving test re-
porting up to 50.0 mg/L FEU (16,17).
The recommended cut-off for all assays that were 
extensively clinically validated for the exclusion of 
VTE and PE in large cohort studies (11,18) is 0.5 
mg/L FEU. All assays and instruments were used 
according to their respective manufacturer’s in-
structions. For each assay, an identical reagent lot 
was used throughout the study. 
Study protocol
Within-run and between-run precision was deter-
mined by analysing assay-specific commercial 
control samples at a low and high concentration 
level in triplicate for 5 consecutive days, as pro-
posed by the Clinical and Laboratory Standards In-
stitute (CLSI) EP15-A3 protocol (19). INNOVANCE D-
Dimer Control 1 and Control 2 (Siemens Health-
care, Marburg, Germany) are lyophilized human 
plasma based products that contain a determined 
amount of D-Dimers and were used for the INNO-
VANCE D-Dimer assay (11). HemosIL D-dimer HS 
500 Control Level 1 and 2 (Instrumentation Labo-
ratory, Milan, Italy) are ready to use, liquid, human 
derived control materials (14) that were analysed 
with the HemosIL D-Dimer HS 500 assay. 
Bias was calculated from between-run precision 
data using the following equation: Bias (%) = 
[(Mean value – Target value)/Target value] x 100.
Measurement uncertainty (MU) was determined 
by analysing INNOVANCE D-dimer calibrator (lot 
561980, target value 4.82 mg/L FEU) on ACL TOP 
550 while with both D-dimer HS 500 calibrator (lot 
B31228, target value 7.34 mg/L FEU) and the pro-
prietary INNOVANCE D-dimer calibrator (lot 
561967, target value 4.81 mg/L FEU) on Sysmex CS-
5100 and Atellica COAG 360. Measurement uncer-
tainty contributors used for MU calculation includ-
ed: bias obtained by 10 replicate measurements of 
respective calibrators, assay repeatability ex-
pressed as within-day CV, and calibrator uncer-
tainty declared by the manufacturer, where de-
fined (i.e. 4.6% for INNOVANCE D-dimer calibrator). 
Expanded MU was expressed as a square root of 
the sum of squares of all MU inputs, multiplied by 
coverage factor k = 2. Obtained results were com-
pared with the total allowable error (TAE) goal de-
rived from biological variation (20). Although MU 
and TAE concepts differ in their origin, when the 
MU calculation is based only on a few independ-
ent variables, as in our case, the two models be-
come identical and the TAE goal is applicable for 
evaluation of MU (21). 
Method comparison was performed as a consecu-
tive study and included parallel analysis of fresh 
plasma samples with a wide range of concentra-
tions from the daily routine that were analysed on 
Sysmex CS-5100, Atellica COAG 360, and ACL TOP 
550, as well as with the VIDAS D-Dimer Exclusion II 
assay on the routinely used miniVidas analyser. 
The cut-off value of 0.5 mg/L FEU was verified fol-
lowing the protocol defined in the CLSI EP28-A3c 
document (22). A total of 20 apparently healthy 
volunteers (10 males and 10 females, median age 
24 years, ranging from 17 to 46) with no known co-
agulation defects, recruited from laboratory staff, 
participated in the study. The cut-off was consid-
ered suitable for our patient population if ≥ 90% 
of results were below 0.5 mg/L FEU.
We also assessed the agreement of D-dimer re-
sults obtained with the compared assays, i.e. the 
number of results that were below or above the 
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predefined cut-off value. The agreement of LPIAs 
with ELFA on miniVidas was assessed for 43 pa-
tient samples used in method comparison, while 
for agreement between LPIAs a total of 63 sam-
ples were used (43 from method comparison and 
20 healthy controls from verification of the cut-off 
value). Additionally, results were separately com-
pared for the group of samples with D-Dimer val-
ues up to 1 mg/L FEU as well as up to 10 mg/L FEU. 
Blood samples were collected into 4.5 ml 0.105 M 
(3.2%) sodium citrate vacutainers (Becton Dickin-
son, Plymouth, United Kingdom), centrifuged 15 
minutes at 2000xg at ambient temperature, and 
analysed, whenever possible, within two hours, 
and no more than four hours from blood collec-
tion. All samples used in method comparison were 
anonymized leftover routine plasma samples oth-
erwise destined for discard. Healthy volunteers 
that participated in the study gave their informed 
consent. The study was part of the verification 
protocol required to be conducted in an accredit-
ed laboratory according to the International 
Standard ISO 15189, and was performed in compli-
ance with the Declaration of Helsinki ethical stand-
ards and under the terms of all relevant local legis-
lation.
Statistical analysis
For precision study performed using commercial 
control samples, mean values, coefficients of varia-
tions (CVs, %), and standard deviations (SDs) were 
reported. Data normality of patient results used 
for method comparison was assessed using the 
Shapiro-Wilk test. Given the non-normal distribu-
tion, Spearman’s rank correlation coefficient (ρ) 
was calculated for the assessment of agreement 
between compared data. Passing and Bablok re-
gression analysis, assisted by Bland-Altman analy-
sis was used for statistical analysis of method com-
parisons. The inter-assay agreement relative to the 
cut-off value was evaluated by the weighted Co-
hen’s kappa coefficient (κ). Statistical analysis was 
carried out using MedCalc Statistical Software ver-
sion 19.1.3 (MedCalc Software Ltd, Ostend, Bel-
gium; https://www.medcalc.org; 2019).
Results
Results of the precision study and estimation of 
bias for Sysmex CS-5100, Atellica COAG 360, and 
ACL TOP 550 analysers are presented in Table 1.
Obtained MU values for Sysmex CS-5100 and Atel-
lica COAG 360 using D-dimer HS 500 calibrator 
were 12.6% and 15.6%, respectively, while using 
INNOVANCE D-dimer calibrator were 12.0% and 
10.0%, therefore fulfilling the TAE criteria (20) of 
28.04%. Measurement uncertainty for ACL TOP 550 
using INNOVANCE D-dimer calibrator was 28.1%.
Comparisons of LPIAs on Sysmex CS-5100, Atellica 
COAG 360 and ACL TOP 550, yielded median val-
Assay INNOVANCE D-Dimer HemosIL D-dimer HS 500
Analyser Sysmex CS-5100 Atellica COAG 360 ACL TOP 550
Control INNOVANCE D-Dimer INNOVANCE D-Dimer HemosIL D-dimer HS 500











Target value (mg/L FEU) 0.30 2.69 0.31 2.81 0.60 1.97
Mean ± SD (mg/L FEU) 0.31 ± 0.01 2.77 ± 0.09 0.31 ± 0.01 2.76 ± 0.05 0.62 ± 0.05 2.01 ± 0.04
Within-run CV (%) 3.6 3.2 3.9 1.6 7.9 1.8
Between-run CV (%) 1.7 5.6 6.9 4.3 4.0 1.9
Bias (%) 3.3 3.0 0 - 1.8 3.3 2.0
SD - standard deviation. FEU - fibrinogen equivalent unit. CV - coefficient of variation.
Table 1. Precision and bias of INNOVANCE D-Dimer assay on Sysmex CS-5100 and Atellica COAG 360, and HemosIL D-Dimer HS 500 
assay on ACL TOP 550
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ues of 1.69 mg/L FEU (interquartile range (IQR): 
0.89-6.52), 1.75 mg/L FEU (IQR: 0.91-6.66) and 1.47 
mg/L FEU (IQR: 0.93-5.61), respectively. High corre-
lations were demonstrated for all assessed com-
parisons, i.e. Spearman’s ρ for the comparison be-
tween Sysmex CS-5100 and Atellica COAG 360 was 
0.99 (95% confidence interval (CI): 0.98 to 1.00), for 
comparison between Sysmex CS-5100 and ACL 
TOP 550 1.00 (95%CI: 0.99 to 1.00) and 1.00 (95%CI: 
0.99 to 1.00) when the results obtained on Atellica 
COAG 360 and ACL TOP 550 were compared. 
For comparison between Sysmex CS-5100 and At-
ellica COAG 360, no significant difference was re-
vealed by Passing-Bablok regression analysis, with 
an equation y = 1.02x + 0 (Figure 1A). Small con-
stant and proportional difference was obtained 
when results of Sysmex CS-5100 and ACL TOP 550 
were compared (y = 0.88x + 0.09) (Figure 1C) and 
for comparison between Atellica COAG 360 and 
ACL TOP 550 (y = 0.85x + 0.08) (Figure 1E). The re-
spective mean biases obtained by Bland-Altman 
analysis were - 0.13 mg/L FEU (95%CI: - 0.29 to 
0.02), 0.20 mg/L FEU (95%CI: - 0.04 to 0.45) and 
0.34 mg/L FEU (95%CI: 0.05 to 0.62), as shown in 
Figures 1B, 1D and 1F. By excluding the four sam-
ples with D-Dimer values above 10 mg/L the re-
sults of method comparison did not differ, yielding 
similarly high correlation coefficients (the lowest 
being 0.97 for the comparison between Sysmex 
CS-5100 and ACL TOP 550), equally negligible dif-
ferences and mean biases between the evaluated 
analysers. When considering the 35 samples with 
values up to 1 mg/L FEU, Spearman’s ρ was 0.97 
for comparison of the same D-Dimer INNOVANCE 
assay between Sysmex CS-5100 and Atellica COAG 
360, with no statistically significant differences ob-
served by Passing-Bablok regression analysis with 
y = 1.04x - 0.01 (intercept 95%CI: - 0.02 to 0; slope 
95%CI: 1.00 to 1.09). However, comparisons of Sys-
mex CS-5100 and Atellica COAG 360 with ACL TOP 
550 yielded ρ of 0.868 and 0.881, respectively. 
Small constant and proportional differences were 
obtained, with y = 1.24x - 0.12 (intercept 95%CI: 
- 0.24 to - 0.04; slope 95%CI: 1.12 to 1.52) for Sys-
mex CS-5100 vs. ACL TOP 550, and y = 1.18x - 0.09 
(intercept 95%CI: - 0.20 to - 0.02; slope 95%CI: 1.06 
to 1.42) for Atellica COAG 360 vs. ACL TOP 550. No 
statistically significant bias using Bland-Altman 
analysis was observed for either of the latter evalu-
ated comparisons.
Additionally, the results of the method compari-
son of Sysmex CS-5100, Atellica COAG 360, and 
ACL TOP 550 with miniVidas are presented in Table 
2.
Moreover, considering the cut-off value of 0.5 
mg/L FEU, a 100% agreement of results was ob-
served for comparison between Sysmex CS-5100 
and Atellica COAG 360. For other comparisons, mi-
nor disagreements were observed, as presented in 
Table 3.
The two discordant samples, when comparing 
ACL TOP 550 with Sysmex CS-5100 and Atellica 
COAG 360, correspond to the healthy volunteers 
Analyser ρ Intercept (95%CI) Slope(95%CI)
Mean bias, mg/L FEU
(95%CI)




(- 1.5 to - 0.3)




(-1 .6 to - 0.4)




(- 1.3 to - 0.01)
ρ - Spearman’s rank correlation coefficient. CI - confidence interval. FEU - fibrinogen equivalent unit.
Table 2. The results of Passing-Bablok regression analysis, Bland-Altman analysis and Spearman’s rank correlation coefficient for D-
Dimer comparison of Sysmex CS-5100, Atellica COAG 360 and ACL TOP 550 with the miniVidas analyser
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Sysmex CS-5100 / 
Atellica COAG 360†
63 96.8 0.93(0.84 to 1.00) ACL TOP 550
Sysmex CS-5100 / 
Atellica COAG 360
Sample 1 0.57 0.41 / 0.48
Sample 2 0.81 0.31 / 0.31
miniVidas
vs.
Sysmex CS-5100 / 
Atellica COAG 360 / 
ACL TOP 550‡
43 97.7 0.85(0.55 to 1.00) miniVidas
Sysmex CS-5100 / 
Atellica COAG 360 / 
ACL TOP 550
Sample 1 0.74 0.33 / 0.31 / 0.38
N - total number of compared samples. CI - confidence interval. FEU - fibrinogen equivalent unit. *Percentage of concordant 
D-Dimer results between compared analysers relative to the cut-off of 0.5 mg/L FEU. †The same two samples were discordant when 
comparing ACL TOP 550 with both Sysmex CS-5100 and Atellica COAG 360. ‡The same sample was discordant when comparing 
miniVidas with Sysmex CS-5100, Atellica COAG 360 and ACL TOP 550.
Table 3. Agreement of D-Dimer results relative to the cut-off value of 0.5 mg/L FEU
included in the verification of the cut-off, yielding 
90% of results below the cut-off. On the contrary, 
all samples from healthy volunteers analysed on 
Sysmex CS-5100 and Atellica COAG 360 were be-
low the cut-off. The median D-dimer values were 
0.20 (IQR: 0.19 to 0.32) on Sysmex CS-5100, 0.19 
(IQR: 0.19 to 0.31) on Atellica COAG 360 and 0.20 
(IQR: 0.12 to 0.32) using ACL TOP 550. Consequent-
ly, the predefined cut-off was verified for all assays 
and analysers, and thus can be safely used in rou-
tine practice for the patient population served in 
our laboratory.
Discussion
This study shows that all evaluated LPIA D-Dimer 
assays confirm satisfactory precision characteris-
tics and negligible biases that are in compliance 
with manufacturer’s claimed values, with the ex-
ception of within-run precision of ACL TOP 550 for 
the low concentration level control sample that 
slightly exceeded the expected imprecision of 6%. 
This is in concordance with data from earlier vali-
dation studies that equally report excellent preci-
sion performance of the respective D-dimer as-
says, with more variable CVs at the low concentra-
tion level (7,23,24). 
As expected, high between-assay comparability 
was demonstrated for the same INNOVANCE D-di-
mer assay applied on two analytical platforms, i.e. 
Sysmex CS-5100 and Atellica COAG 360. High com-
parability was also evidenced when comparing 
this assay with the other LPIA HemosIL D-dimer 
HS500 applied on ACL TOP 550, which can be ex-
plained by the fact that both assays utilize the 
same 8D3 monoclonal antibody. Even the compar-
ison of those immunoturbidimetric assays with 
ELFA, that is designed along the same principles as 
the reference microplate ELISA, yielded satisfacto-
ry agreement results, i.e. correlation coefficients 
equal or greater than 0.93, with only small con-
stant and/or proportional differences and biases. 
A larger dispersion of results was observed above 
the cut-off value and in proportion with increasing 
D-dimer results. This finding bears no particular 
clinical significance since D-dimer should not be 
used for any kind of patient monitoring but for its 
main indication, which is ruling out VTE or PE. 
However, in the light of the recent coronavirus dis-
ease 2019 outbreak as well as various medical con-
https://doi.org/10.11613/BM.2020.030705 Biochem Med (Zagreb) 2020;30(3):030705 
  7
Lapić I. et al. Verification of immunoturbidimetric D-Dimer assays
Figure 1. Passing Bablok regression analysis for comparison of D-Dimer results between: (A) Sysmex CS-5100 vs. Atellica COAG 360, 
(C) Sysmex CS-5100 vs. ACL TOP 550 and (E) Atellica COAG 360 vs. ACL TOP 550. Corresponding scatter diagrams obtained by Bland-
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ditions additionally complicated by thromboem-
bolism and inflammation, D-Dimers emerge as a 
valuable prognostic biomarker, with increasing 
values being associated with disease severity and 
higher mortality rates (25,26). Given the observed 
differences at higher D-Dimer concentrations, it is 
a requirement, as for all immunoassays, to provide 
longitudinal patient monitoring with the same as-
say whenever possible.
We also obtained clinically acceptable inter-assay 
agreement between all assessed assays when the 
recommended cut-off value is used, with occa-
sional discrepancies near the cut-off. Discordance 
of the one sample with the result above the cut-off 
with ELFA but below with all LPIAs can be attribut-
ed to different methodological principles, i.e. ELFA 
being more specific by using two monoclonal an-
tibodies and a more sensitive detection method, 
heterogeneity of D-dimers structure, variable re-
activity of antibodies to different kinds of fibrin 
derivatives or cross-reactivity with non-cross-
linked fibrinogen and fibrin degradation products 
(1,9,27). Moreover, observed cases of disagreement 
regarding the cut-off and occasional different clas-
sification of healthy controls with LPIAs imply that 
different clinical performance can be found even 
between D-dimer assays based on the same meth-
odological principle. This finding is especially evi-
dent when evaluating MU results obtained by ana-
lysing the non-proprietary calibrator on ACL TOP 
550, indicating that interchangeable use of calibra-
tors might not be possible. However, to get a true 
insight, it would be valuable to assess the perfor-
mance of reference material with D-dimer values 
near the clinical decision threshold. 
The present study has some limitations. Firstly, the 
used TAE goal is probably outdated and not in line 
with the current state of the art for existing D-Di-
mer methods and in accordance with improve-
ments in the field. However, more recent data on 
biological variation in the haemostasis field is still 
lacking (1). Secondly, we are not aware if any of the 
observed discrepancies between the compared 
methods is due to analytical interferences, such as 
RF or heterophilic antibodies (28). Finally, a more 
profound assessment of the cut-off on a popula-
tion aged over 50 years should be performed to 
verify the recommended age-adjusted cut-off ap-
proach (29). Hereby we only verified the applica-
bility of the proposed cut-off concentration of 0.5 
mg/L FEU to our population using a small number 
of qualified reference individuals. This threshold is 
universally accepted for the exclusion of VTE and 
PE, based on previous extensive clinical validation 
studies in large cohorts of patients with suspected 
VTE and PE where imaging techniques were used 
for diagnosis confirmation (11,18).
In conclusion, the results of our study prove the 
analytical validity of the LPIAs INNOVANCE D-dim-
er and HemosIL D-dimer HS500, their almost equal 
discriminatory characteristics, and suggest that 
they might serve as a valid alternative to the ELFA 
method. Furthermore, full automation, the possi-
bility of D-dimer analysis on the coagulation ana-
lysers simultaneously with other coagulation tests, 
and shorter turnaround time makes them attrac-
tive for use in daily laboratory practice. However, 
the occasional differences observed once again 
address the well-known differences between im-
munoassays, which are for D-dimers additionally 
complicated by their structure complexity, and 
highlight the need for further efforts to provide 
standardization of different D-dimer assays. 
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